Foods for Special Medical Purposes in Oncology: Nutrition Support & Oral Mucositis Adjunct

Manuscript type: Narrative review and clinical-development perspective

Keywords: cancer malnutrition; cancer cachexia; oral nutritional supplements; foods for special medical purposes; medical foods; oral mucositis; Streptococcus salivarius K12

Abstract

Cancer-related malnutrition is driven by reduced intake, treatment toxicity, and tumour- and host-related metabolic derangement; it is therefore not adequately addressed by a generic “healthy food” approach. Foods for special medical purposes (FSMPs) in the European Union and medical foods in the United States provide regulatory categories for nutritionally formulated products used under clinical supervision to manage disease-associated nutritional requirements. This review sets out a clinically usable framework for oncology products: screen early; establish whether oral intake is adequate; use counselling and symptom control first; introduce an oral nutritional supplement or FSMP when oral intake remains inadequate; and escalate enteral or parenteral support when the gastrointestinal tract or swallowing function makes oral support insufficient.[1, 2]

The evidence base supports nutritional support as supportive care rather than anticancer therapy. In an 8-week gastrointestinal-cancer trial, an omega-3-enriched oral nutritional supplement improved patient-generated nutritional assessment and several quality-of-life domains but did not improve biochemical nutrition markers; high dropout and small per-protocol samples limit inference.[3] A multicentre trial of a hypercaloric, high-protein formula enriched with leucine, EPA/DHA, fibre and beta-glucans reported gain in muscle mass only in the enriched-formula arm, but only 37 of 57 enrolled participants completed the intervention.[4] The most defensible product claim is consequently dietary management of cancer-related malnutrition or nutritional risk in a defined population, supported by clinically meaningful nutritional and functional endpoints—not a claim to treat cancer, cachexia biology, or treatment toxicity.

Patients receiving head-and-neck radiotherapy form a high-value subgroup because oral mucositis can directly interrupt oral intake. A double-blind trial in 160 patients found that Streptococcus salivarius K12 lozenges reduced severe oral mucositis from 54.2% to 36.6%, with shorter duration; adverse events were similar between groups.[5] This is promising adjunctive evidence for oral-complication management, but K12 is not itself a complete FSMP and should not be represented as a substitute for energy-protein nutrition support. A co-development programme would need separate clinical and regulatory substantiation for the FSMP formula and the probiotic adjunct.

1. Introduction

Cancer care creates nutritional risk through several converging pathways: anorexia, dysphagia, nausea, vomiting, altered taste, malabsorption, surgery, mucositis, treatment-related inflammation, reduced activity, and catabolic metabolic change. In an oncology nutrition trial, the authors describe cancer therapy–associated mucositis, taste aversion, nausea and vomiting as drivers of appetite loss, and identify nutritional status as relevant to therapeutic efficacy.[3] ESPEN’s evidence-based cancer nutrition guideline similarly identifies malnutrition and loss of muscle mass as frequent, clinically harmful features of cancer and recommends regular screening and stepwise nutritional intervention.[1]

This clinical context distinguishes FSMPs and medical foods from ordinary foods, supplements, and wellness products. An oncology nutrition product must solve a specific nutritional-management problem: for example, a patient with reduced intake who needs a high-energy, high-protein oral formula; a patient with dysphagia who needs an appropriately textured and nutritionally complete formulation; or a patient receiving radiotherapy who needs oral support compatible with painful mucositis. The commercial formulation may be sophisticated, but the central therapeutic objective remains nutritional adequacy and preservation of function—not direct tumour control.[1, 6]

This paper has three aims:

1. define the EU FSMP and US medical-food concepts relevant to oncology;
2. synthesize the clinical rationale and limits of oral nutrition support; and
3. propose a development and evidence framework for an oncology-focused product platform, including the cautious use of BLIS K12 as a separately substantiated oral-mucositis adjunct.

2. Regulatory concepts: FSMP is not simply a fortified food

2.1 European Union

EU law categorizes FSMPs as nutritionally complete standard formulas, nutritionally complete disease-adapted formulas, or nutritionally incomplete standard/disease-adapted formulas. Complete products may serve as a sole source of nourishment when used as directed; they may also supplement or partially replace the diet.[6] The formulation must be based on sound medical and nutritional principles, and its safe, beneficial and effective use for the target group’s specific nutritional requirements must be demonstrated by generally accepted scientific data.[6]

For an adult oncology FSMP, the label must state that the product is to be used under medical supervision; whether it is suitable as a sole source of nourishment; the relevant age group; and, where relevant, precautions or contraindications. It must also specify “For the dietary management of …” followed by the disease, disorder, or medical condition, and describe the formulation properties that make the product useful for that dietary management.[6] Nutrition and health claims are prohibited for FSMPs under this regulation.[6]

These requirements have a practical consequence: “for oncology patients” alone is generally too broad to be a scientifically coherent nutritional indication. A more defensible indication is one tied to a nutritional phenotype and care setting, such as: “For the dietary management of disease-related malnutrition in adults with cancer who cannot meet energy and protein needs through diet alone.” Any disease-adapted feature—such as altered macronutrient distribution, fibre type, osmolality, protein source, micronutrient profile, or texture—must have a stated clinical rationale.[6]

2.2 United States

The US definition of a medical food is a food formulated to be consumed or administered enterally under physician supervision for the specific dietary management of a disease or condition with distinctive nutritional requirements established by medical evaluation.[7] This overlaps materially with the EU concept but should not be treated as legally interchangeable. Product development should therefore establish the intended regulatory route early and build one core evidence package with jurisdiction-specific label, notification, and claims review.

2.3 Boundaries that protect patients and programmes

Three boundaries should be explicit in any dossier and promotional material:

• FSMP/medical food vs. ordinary supplement. The former is used under clinical supervision for dietary management of a defined condition with distinctive nutritional requirements; it is not simply a nutrient-containing consumer product.[6, 7]
• Dietary management vs. treatment of cancer. The clinical claim should concern nutrient delivery, nutritional status, body composition, function, or ability to sustain oral intake—not tumour response, survival, or replacement of anticancer therapy.
• Formula vs. adjunct. A complete or incomplete nutrition formula and a probiotic oral-health adjunct have different intended purposes, evidence packages, risks, and regulatory considerations. Combining them in a single product claim without dedicated evidence would create avoidable substantiation risk.

3. Clinical place in oncology care

ESPEN recommends that institutions establish procedures to screen, prevent, assess, monitor and treat malnutrition, and that nutritional needs be met stepwise—from counselling through parenteral nutrition—except where end-of-life goals alter the balance of benefits and burdens.[1] A practical oncology pathway is therefore:

1. Screen at diagnosis and repeatedly during treatment: record weight trajectory, intake, symptoms affecting intake, muscle/function measures where feasible, and patient-reported nutrition impact symptoms.
2. Treat reversible barriers: pain, nausea/vomiting, constipation, diarrhoea, xerostomia, dysgeusia, dysphagia, depression, dental disease, and mucositis require active management alongside nutrition support.
3. Optimize oral intake: individualized dietetic counselling, food fortification, meal timing and texture adaptation remain foundational.
4. Add ONS/FSMP when diet remains inadequate: choose a formula that matches energy/protein needs, tolerance, intake capacity, comorbidity, and intended duration.
5. Escalate route when necessary: enteral feeding is preferable when the gut is usable but oral intake is insufficient; parenteral nutrition is reserved for situations in which enteral nutrition is not feasible or adequate.
6. Monitor response and burden: weight alone is insufficient. Track intake, symptom burden, adherence, functional status, body composition when available, and treatment continuity.[1, 3]

This sequence prevents a common failure mode: treating the product as the intervention while leaving unaddressed the symptom that makes drinking it impossible. In GI cancer, dysphagia and vomiting make dietary intervention difficult, and the available evidence is heterogeneous.[3]

4. What oral nutritional supplement trials show—and what they do not

4.1 Nutritional status and quality of life

In a randomized study of 58 patients with stage II–IV gastrointestinal cancers, 40 completed 8 weeks of routine counselling plus twice-daily omega-3-enriched ONS or counselling alone. The intervention increased total energy and protein intake, and within-arm improvements were observed in patient-generated subjective global assessment and several quality-of-life/symptom measures.[3] No significant group differences were seen in inflammatory cytokines or conventional biochemical nutrition markers.[3] The study supports feasibility and a possible patient-centred benefit, but attrition was 31% and analysis was per protocol; it should not anchor broad claims of metabolic reversal.[3]

The ALISENOC multicentre double-blind trial compared two isocaloric/isoproteic high-energy, high-protein formulations for 8 weeks in malnourished cancer patients. The disease-adapted formula contained extra-virgin olive oil, EPA/DHA, beta-glucans and leucine; 37 of 57 enrolled patients completed intervention. The enriched formula arm gained approximately 1.9 kg of muscle mass on average, whereas the comparator arm lost approximately 0.7 kg, and nutritional-category recovery occurred only in the enriched arm.[4] This result is clinically interesting, but the completed sample is small and tumour types were predominantly GI and lung; it needs replication with prespecified, patient-relevant endpoints.

A small 2025 double-blind study of an FSMP in nutritional-risk oncology outpatients found lower post-intervention nutritional risk and improved gait speed, timed-up-and-go performance, grip strength and upper-limb muscle mass after 8 weeks, but did not find a significant change in sarcopenia prevalence. Only 25 of 36 enrolled participants completed the study.[8] Its findings are directionally consistent with a nutrition-support purpose but are not sufficient to establish an oncology-wide product effect.

4.2 Implications for formula design

The evidence does not establish a universal “best” cancer formula. It does support a design approach that begins with delivery of enough energy and high-quality protein in a volume, texture, flavour profile, and dosing schedule that a symptomatic patient can actually consume. Disease-adapted ingredients should be justified individually and evaluated in a formula-level trial; adding EPA/DHA, leucine, fibre or bioactives does not automatically prove benefit.[3, 4]

For an oral oncology FSMP, the minimum technical dossier should address:

• energy and protein delivered per serving and per intended daily dose;
• amino-acid and protein-source rationale, including tolerability and allergens;
• fat, carbohydrate and fibre profile, including implications for glycaemic management, diarrhoea/constipation, and delayed gastric emptying;
• micronutrient provision across the intended dose range, avoiding unnecessary excess exposure;
• osmolality, viscosity, texture and flavour options relevant to mucositis and dysphagia;
• microbiological quality, stability, compatibility with oral/enteral delivery, and storage after opening;
• contraindications and precautions, particularly renal, hepatic, metabolic and swallowing-related conditions.[6]

5. Head-and-neck cancer and oral mucositis: a population where intake support and oral care intersect

Oral mucositis causes painful inflammation and ulceration, impairing swallowing, drinking and eating; it can lead to anorexia, weight loss, infection risk and treatment interruption.[9] The 2019 systematic review of probiotic interventions notes that mucositis can become severe enough that enteral or parenteral feeding is required, and that severe mucositis can reduce treatment dose intensity or temporarily interrupt therapy.[10] Thus, oral mucositis is both an oral-care complication and a nutritional-care trigger.

A small 15-participant, open-label pilot trial of a multi-ingredient nutritional supplement reported a substantial fall in WHO oral-toxicity grade and more days with normal food intake, but its sample size, unblinded design, mixed oncologic treatments and manufacturer involvement make it hypothesis-generating only.[9] Such data should not be used to justify a mature therapeutic claim.

The evidence for S. salivarius K12 is stronger but pertains to an adjunctive probiotic, not nutritional completeness. In a prospective randomized, double-blind, placebo-controlled trial in 160 patients receiving radiotherapy for malignant head-and-neck tumours, K12 lozenges were taken three times daily during radiotherapy. Severe oral mucositis occurred in 36.6% of the K12 group versus 54.2% of placebo recipients, and the K12 group had shorter severe-mucositis duration; adverse events were similar, with two mild-to-moderate gastrointestinal reactions judged associated with the lozenges.[5] A 2024 meta-analysis covering 12 studies and 1,055 patients also found fewer severe mucositis events with probiotics overall, although effects varied by tumour type, treatment regimen and region.[11]

The appropriate scientific interpretation is cautious. A K12 product may be an attractive supportive-care adjunct in radiotherapy-associated head-and-neck mucositis, particularly where it helps preserve oral intake. It is not evidence that K12 treats cancer, reverses cachexia, or can replace nutrition support. Patients with severe mucositis, neutropenia, mucosal barrier injury, central lines, or other high-risk infectious conditions should have product use assessed by the treating oncology and infectious-disease teams; the available trial evidence does not eliminate the need for individual risk assessment.[10]

6. A product-development framework for an oncology FSMP platform

6.1 Define the target population narrowly

A credible first indication should not be “all oncology patients.” A practical development population is adults with solid tumours who are at nutritional risk or malnourished, retain a functioning gastrointestinal tract, and cannot meet energy/protein needs through diet alone. The first commercialization subgroup may be GI or head-and-neck cancer, because their nutritional barriers are tangible and measurable.[1, 3, 9]

6.2 Establish the product architecture

A rational platform could include:

• Core complete oral FSMP: high-energy/high-protein formulation for partial or complete nutritional support, with evidence-based micronutrient specification and multiple sensory/texture formats.
• Mucositis-compatible variant: neutral flavour, non-acidic profile, viscosity adapted to painful swallowing, and dose flexibility to enable frequent small-volume intake. This variant is a design hypothesis that needs acceptability data in the intended population.
• Separate BLIS K12 adjunct: lozenge or oral format developed and labelled separately, with an oral-mucositis endpoint strategy. It should not be embedded into a formula without stability, compatibility, safety and clinical-interaction evidence.[5, 6]

6.3 Clinical evidence plan

The pivotal study should be randomized, controlled and pragmatic enough to reflect oncology care. Essential features include:

• Population: pre-specified tumour types, treatment setting, nutritional-risk definition, baseline intake deficit and exclusion criteria.
• Comparator: standardized dietetic counselling plus usual care, or an isocaloric/isoproteic comparator when testing a disease-adapted formula.
• Duration: at least 8–12 weeks, with follow-up sufficient to distinguish transient intake effects from sustained functional benefit.
• Primary endpoint: a clinically interpretable nutrition endpoint such as change in PG-SGA category, achievement of prescribed energy/protein targets, or a composite including nutritional status and treatment completion.
• Key secondary endpoints: lean mass assessed by a justified technique, handgrip strength or other function measure, treatment interruptions/dose reductions, hospitalizations, quality of life, symptom burden, adherence, adverse events and healthcare utilization.
• Head-and-neck substudy: severe oral-mucositis incidence and duration, ability to maintain oral intake, feeding-tube initiation, opioid use and unplanned treatment breaks. If K12 is evaluated, it should be randomized independently or factorially so that formula and probiotic effects can be separated.[5, 9]

6.4 What would change the conclusion

The pivotal uncertainty is whether a formula that is disease-adapted beyond energy and protein improves outcomes that matter to patients and oncology teams—function, treatment tolerance, hospitalization and quality of life—beyond a well-tolerated matched standard formula plus high-quality dietetic care. This requires an adequately powered comparative trial, not inference from individual ingredients.[3, 4, 8]

7. Discussion

The research supports early, structured nutritional care in oncology. It does not support a monolithic claim that one formula suits every tumour type, treatment regimen or symptom complex. The strongest operational insight is that nutritional products must be embedded in a clinical pathway: screen, assess barriers to intake, prescribe a formulation and dose, monitor adherence and response, and escalate route when oral support fails.[1, 3]

The available trials point to benefits in nutritional assessment, intake, selected quality-of-life measures, muscle mass and physical performance, but their limitations are material: small samples, heterogeneous cancers, short intervention periods, variable comparators and attrition.[3, 4, 8] These limitations should shape both product claims and evidence-generation priorities.

The BLIS project has a particularly relevant but separate opportunity. The K12 radiotherapy trial provides a patient-centred rationale for exploring oral-mucositis support in head-and-neck oncology.[5] If oral pain and mucositis prevent intake, preventing or shortening severe mucositis could indirectly support nutritional goals. That causal chain is plausible, but it has not yet been demonstrated as a combined FSMP-plus-K12 platform outcome. A staged development approach—first substantiate nutrition support and K12 oral-mucositis adjunct effects separately, then test the integrated care pathway—would be more credible scientifically and more resilient regulatorily.

8. Conclusions

Oncology FSMPs and US medical foods should be developed as clinically supervised tools for the dietary management of a precisely defined nutritional problem, not as cancer therapies or generic “immune-support” products. EU FSMP law requires sound medical and nutritional principles and generally accepted scientific evidence that the formulation safely, beneficially and effectively meets the target group’s specific nutritional requirements.[6] The evidence supports oral nutrition support as one component of stepwise cancer care, with the clearest claims centred on adequacy of intake, nutritional status, functional preservation and quality of life rather than anticancer efficacy.[1, 3]

A disease-adapted formula for cancer-related malnutrition should begin with high acceptability and reliable energy-protein delivery, then test any added ingredients in a formula-level comparative trial. BLIS K12 has encouraging randomized evidence as an adjunct for radiotherapy-associated severe oral mucositis in head-and-neck cancer, but it should remain a distinct, clinically supervised oral-care component until combined-formulation safety, stability and efficacy are directly demonstrated.[5]

Selected references

• Muscaritoli M, Arends J, Bachmann P, et al. ESPEN practical guideline: Clinical Nutrition in cancer. Clinical Nutrition. 2021.[2]
• Arends J, Bachmann P, Baracos V, et al. ESPEN guidelines on nutrition in cancer patients. Clinical Nutrition. 2017.[1]
• European Commission. Commission Delegated Regulation (EU) 2016/128 as regards specific compositional and information requirements for foods for special medical purposes.[6]
• U.S. Food and Drug Administration. Medical Foods Guidance Documents & Regulatory Information.[7]
• Sim E-K, Kim J-M, Lee S, et al. The effect of omega-3 enriched oral nutrition supplement on nutritional indices and quality of life in gastrointestinal cancer patients: a randomized clinical trial. Asian Pacific Journal of Cancer Prevention. 2022.[3]
• Vidal Casariego A, García Luna PP, Villazón González F, et al. Impact of an oral nutritional supplement with bioactive compounds on improving nutritional status, body composition and quality of life in cancer patients: the ALISENOC study. Clinical Nutrition ESPEN. 2023.[4]
• Fu J, Yu K, Zhang Y, Bao Y-Y, Li S. Effects of FSMP on nutrition status and sarcopenia among nutritional-risk cancer patients: a randomized, double-blind, placebo-controlled study. 2025.[8]
• Peng X-C, Li Z, Pei Y, et al. Streptococcus salivarius K12 alleviates oral mucositis in patients undergoing radiotherapy for malignant head and neck tumors: a randomized controlled trial. Journal of Clinical Oncology. 2024.[5]
• Zhu Z, Pan W, Ming X, et al. The effect of probiotics on severe oral mucositis in cancer patients undergoing chemotherapy and/or radiotherapy: a meta-analysis. Journal of Oral and Maxillofacial Surgery. 2024.[11]
• Picó-Monllor JA, Mingot-Ascencao JM. Search and selection of probiotics that improve mucositis symptoms in oncologic patients: a systematic review. Nutrients. 2019.[10]

" } }